Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction

描述（由申请人提供）：低剂量他莫昔芬治疗霍奇金淋巴瘤幸存者以降低乳腺癌风险罩辐射一直是HL治疗的基石;但是，在此情况下，在30岁之前接受地幔照射治疗的HL女性幸存者患乳腺癌（BC）的风险增加20- 55倍。与BRCA突变携带者的风险相当手术预防在降低BC风险方面非常有效，但这种侵入性策略并不适合所有女性。药物干预是存在的，但只有他莫昔芬被批准用于尚未达到更年期的年轻女性。标准剂量的他莫昔芬（每天20毫克）与不良副作用有关，但最近的研究奠定了令人信服的基础，即较低剂量的他莫昔芬在降低BC风险方面可能同样有效，而且副作用更少。我们假设，他莫昔芬以较低剂量（每日5 mg）给药对于儿童期或年轻成人诊断的HL女性成年幸存者而言，是一种有效且安全的非手术风险降低干预措施。因此，使用低剂量他莫昔芬的IIb期随机、双盲、安慰剂对照试验（5 mg/天），我们的目的是1）确定低剂量他莫昔芬2年疗程对化学预防有效性的替代生物标志物的影响; 2）确定低剂量他莫昔芬在该人群中的安全性和耐受性;以及，作为探索性目的，3）检查与辐射相关BC风险相关的几个明确定义的人口统计学和临床特征对该干预的风险：受益比的修改效果。提供知情同意书的合格受试者将随机接受5 mg/天他莫昔芬与安慰剂，持续两年。结果将包括几种疗效的替代生物标志物，包括乳腺摄影乳腺密度（MBD，主要终点）、乳腺细胞形态学和增殖指标以及胰岛素生长因子。将使用患者报告的结局以及血脂谱、凝血因子和骨转换标志物作为客观终点，仔细随访受试者的安全性和耐受性。将被检查的风险修饰因子包括年龄、绝经状态、既往激素使用、体重指数、良性乳腺疾病个人史和癌症家族史，以及胸部辐射剂量、暴露年龄和胸部辐射潜伏期。每组127例的样本量将能够检测到低剂量他莫昔芬相对于安慰剂的MBD降低20%，功效为80%。我们已经在我们的五个机构联盟中确定了900多名潜在合格的受试者，这些机构拥有完善的基础设施，可以长期随访儿童癌症幸存者，从而证明我们将有足够大的样本库来吸引合格的患者人群并完成研究。本研究完成后，我们希望为发生BC的高风险HL幸存者确定一种耐受性良好的风险降低方案。低剂量他莫昔芬用于霍奇金淋巴瘤生存者降低乳腺癌风险 公共卫生相关性：霍奇金淋巴瘤（HL）的生存率很高，但胸部放疗（RT）一直是治疗的基石，年轻时暴露于胸部RT的HL女性患乳腺癌（BC）的风险增加了20至55倍。他莫昔芬可将BC的风险降低50%，但以一些不良副作用为代价，而最近的研究表明，较低剂量的他莫昔芬可能在降低BC风险方面同样有效，副作用较少。我们认为，他莫昔芬每日5 mg给药将是暴露于胸部RT的BC高风险女性HL幸存者的理想非手术风险降低干预措施;因此，我们计划在IIb期临床试验中检验这一假设。

DESCRIPTION (provided by applicant): Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction Mantle radiation has been a cornerstone of HL treatment; however, female survivors of HL treated with mantle irradiation before age 30 have a 20- to 55-fold increased risk of developing breast cancer (BC) - a risk that is comparable to that of BRCA mutation carrierrs Surgical prophylaxis is very effective in reducing the risk of BC, but such invasive strategies are not suitable for all women. Pharmacologic interventions exist, but only tamoxifen is approved for use in young women who have not yet reached menopause. Standard-dose tamoxifen (20 mg daily) is associated with undesirable side effects, but recent studies have laid convincing groundwork that tamoxifen at lower doses may be similarly efficacious in reducing BC risk with fewer side effects. We hypothesize that tamoxifen administered at a lower dose (5 mg daily) would be both an efficacious and safe non-surgical risk reduction intervention for female adult survivors of HL diagnosed during childhood or as a young adult. Thus, using a Phase IIb randomized, double-blind, placebo-controlled trial of low-dose tamoxifen (5 mg daily) in long-term female HL survivors treated with chest radiation, we aim to 1) Determine the impact of a two-year course of low-dose tamoxifen on well-established surrogate biomarkers of chemopreventive efficacy; 2) Establish the safety and tolerability of low-dose tamoxifen in this population; and, as an exploratory aim, 3) Examine the modifying effect of several well-defined demographic and clinical characteristics associated with radiation-related BC risk on the risk:benefit ratio from this intervention. Eligible subjects who provide informed consent will be randomized to 5 mg per day of tamoxifen versus placebo for two years. Outcomes will include several surrogate biomarkers of efficacy, including mammographic breast density (MBD, primary endpoint), breast cytomorphologic and proliferation measures, and insulin growth factors. Subjects will be carefully followed for safety and tolerability using patient-reported outcomes as well as lipid profiles, clotting factors, and markers of bone turnover as objective endpoints. Risk modifiers that will be examined include age, menopausal status, prior hormone use, body mass index, personal history of benign breast disease, and family history of cancer, as well as chest radiation dose, age at exposure, and latency from chest radiation. A sample size of 127 per arm will be able to detect a 20% reduction in MBD with low-dose tamoxifen relative to placebo with 80% power. We have identified over 900 potentially eligible subjects within our consortium of five institutions that have well-developed infrastructure to follow childhood cancer survivors long-term, thus demonstrating that we will have a sufficiently sized pool to draw the eligible patient population from and complete the study. At completion of this study, we hope to identify a well-tolerated risk reduction option for HL survivors that are at high risk for developing BC. Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction Public Health Relevance: Survival from Hodgkin lymphoma (HL) is excellent, but chest radiotherapy (RT) has been a cornerstone of treatment, and women with HL exposed to chest RT when they are young have a 20- to 55-fold increased risk of developing breast cancer (BC). Tamoxifen reduces the risk of BC by 50%, but at the cost of some undesirable side effects, while more recent studies suggest that lower dose tamoxifen may be similarly efficacious in reducing BC risk with fewer side effects. We believe that tamoxifen administered at 5 mg daily would be an ideal non-surgical risk reduction intervention for female HL survivors exposed to chest RT at high risk for BC; therefore, we plan to test this hypothesis in a Phase IIb clinical trial.